DK1718677T3 - Monovalente antistoffragmenter egnede som terapeutiske midler - Google Patents

Monovalente antistoffragmenter egnede som terapeutiske midler

Info

Publication number: DK1718677T3
Authority: DK; Denmark
Prior art keywords: monovalent antibody; therapeutic agents; antibody fragments; fragments suitable; monovalent
Prior art date: 2003-12-19

Application number

DK04814762.3T

Other languages

English (en)

Inventor

Arthur Jyh-Yen Huang

Ralph H Schwall

Daniel G Yansura

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-19

Filing date

2004-12-17

Publication date

2012-07-09

2004-12-17 Application filed by Genentech Inc filed Critical Genentech Inc

2012-07-09 Application granted granted Critical

2012-07-09 Publication of DK1718677T3 publication Critical patent/DK1718677T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK04814762.3T 2003-12-19 2004-12-17 Monovalente antistoffragmenter egnede som terapeutiske midler DK1718677T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53140903P	2003-12-19	2003-12-19
PCT/US2004/042619 WO2005063816A2 (en)	2003-12-19	2004-12-17	Monovalent antibody fragments useful as therapeutics

Publications (1)

Publication Number	Publication Date
DK1718677T3 true DK1718677T3 (da)	2012-07-09

Family

ID=34738648

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04814762.3T DK1718677T3 (da)	2003-12-19	2004-12-17	Monovalente antistoffragmenter egnede som terapeutiske midler

Country Status (21)

Country	Link
US (5)	US20050227324A1 (da)
EP (2)	EP1718677B1 (da)
JP (2)	JP2008504007A (da)
KR (1)	KR100956913B1 (da)
CN (1)	CN1922210A (da)
AT (1)	ATE554107T1 (da)
AU (1)	AU2004309347B2 (da)
BR (1)	BRPI0417107A (da)
CA (1)	CA2548757A1 (da)
CY (1)	CY1112862T1 (da)
DK (1)	DK1718677T3 (da)
ES (1)	ES2384569T3 (da)
IL (2)	IL175885A (da)
MX (1)	MXPA06006985A (da)
NZ (1)	NZ547438A (da)
PL (1)	PL1718677T3 (da)
PT (1)	PT1718677E (da)
RU (1)	RU2006126097A (da)
SI (1)	SI1718677T1 (da)
WO (1)	WO2005063816A2 (da)
ZA (1)	ZA200604864B (da)

Families Citing this family (205)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
PT1392359E (pt)	2001-05-11	2010-01-27	Ludwig Inst For Cancer Res Ltd	Proteínas de ligação específica e suas utilizações
US20100056762A1 (en)	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
WO2005063816A2 (en) *	2003-12-19	2005-07-14	Genentech, Inc.	Monovalent antibody fragments useful as therapeutics
US7476724B2 (en) *	2004-08-05	2009-01-13	Genentech, Inc.	Humanized anti-cmet antibodies
US20060074225A1 (en) *	2004-09-14	2006-04-06	Xencor, Inc.	Monomeric immunoglobulin Fc domains
EP1868648B1 (en) *	2005-03-25	2015-04-15	Genentech, Inc.	Methods and compositions for modulating hyperstabilized c-met
HUE026303T2 (hu)	2005-07-25	2016-06-28	Emergent Product Dev Seattle	B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
AR056142A1 (es) *	2005-10-21	2007-09-19	Amgen Inc	Metodos para generar el anticuerpo igg monovalente
US10155816B2 (en) *	2005-11-28	2018-12-18	Genmab A/S	Recombinant monovalent antibodies and methods for production thereof
US9181344B2 (en) *	2005-12-15	2015-11-10	Genmab A/S	Use of effector-function-deficient antibodies for treatment of auto-immune diseases
JP2009519983A (ja)	2005-12-20	2009-05-21	アラーナ・テラピューティクス・リミテッド	部分的な新世界ザル結合領域を有するキメラ抗体
EA017417B1 (ru)	2006-02-01	2012-12-28	Сефалон Астралия Пти Лтд.	КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ
TW200812615A (en)	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CN105837690A (zh)	2006-06-12	2016-08-10	新兴产品开发西雅图有限公司	具有效应功能的单链多价结合蛋白
GB0614780D0 (en) *	2006-07-25	2006-09-06	Ucb Sa	Biological products
MY150756A (en)	2006-08-21	2014-02-28	Hoffmann La Roche	Tumor theraphy with an anti-vegf antibody
US8680252B2 (en) *	2006-12-10	2014-03-25	Dyadic International (Usa), Inc.	Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
US9862956B2 (en)	2006-12-10	2018-01-09	Danisco Us Inc.	Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
WO2008091701A2 (en)	2007-01-25	2008-07-31	Dana-Farber Cancer Institute	Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
JP2010518115A (ja)	2007-02-09	2010-05-27	ジェネンテック，インコーポレイテッド	抗Ｒｏｂｏ４抗体およびそれらのための使用
CA2680854C (en)	2007-03-15	2017-02-14	Ludwig Institute For Cancer Research	Treatment method using egfr antibodies and src inhibitors and related formulations
BRPI0811857A2 (pt) *	2007-05-14	2014-10-21	Biogen Idec Inc	Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
EP3176264B1 (en) *	2007-05-30	2018-09-26	Postech Academy-Industry- Foundation	Immunoglobulin fusion proteins
US20110045007A1 (en) *	2007-05-31	2011-02-24	Genmab A/S	Fusion or linked proteins with extended half life
WO2008145142A1 (en)	2007-05-31	2008-12-04	Genmab A/S	Stable igg4 antibodies
WO2008145141A1 (en) *	2007-05-31	2008-12-04	Genmab A/S	Method for extending the half-life of exogenous or endogenous soluble molecules
WO2008145138A1 (en) *	2007-05-31	2008-12-04	Genmab A/S	Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
WO2008145137A2 (en) *	2007-05-31	2008-12-04	Genmab A/S	Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
EP2167669A2 (en)	2007-05-31	2010-03-31	Genmab A/S	Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
MX2010001757A (es)	2007-08-14	2010-09-14	Ludwig Inst Cancer Res	Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
US7982016B2 (en)	2007-09-10	2011-07-19	Amgen Inc.	Antigen binding proteins capable of binding thymic stromal lymphopoietin
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
US9879267B2 (en) *	2008-03-14	2018-01-30	Genentech, Inc.	Genetic variations associated with drug resistance
AU2009234277B2 (en)	2008-04-11	2014-12-04	Aptevo Research And Development Llc	CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
PA8849001A1 (es)	2008-11-21	2010-06-28	Lilly Co Eli	Anticuerpos de c-met
EP3153524B1 (en)	2008-12-03	2025-04-23	Genmab A/S	Antibody variants having modifications in the constant region
EP2210902A1 (en)	2009-01-14	2010-07-28	TcL Pharma	Recombinant monovalent antibodies
CN101830986A (zh) *	2009-03-13	2010-09-15	北京表源生物技术有限公司	一种融合蛋白多聚体
BRPI1014089A2 (pt)	2009-04-02	2016-04-19	Roche Glycart Ag	anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
AU2010233994A1 (en)	2009-04-07	2011-09-22	Roche Glycart Ag	Bispecific anti-ErbB-3/anti-c-Met antibodies
MX2011010158A (es)	2009-04-07	2011-10-17	Roche Glycart Ag	Anticuerpos biespecificos anti-erbb-2/anti-c-met.
DK2417156T3 (da)	2009-04-07	2015-03-02	Roche Glycart Ag	Trivalente, bispecifikke antistoffer
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
WO2010146059A2 (en)	2009-06-16	2010-12-23	F. Hoffmann-La Roche Ag	Biomarkers for igf-1r inhibitor therapy
US8568719B2 (en)	2009-08-13	2013-10-29	Crucell Holland B.V.	Antibodies against human respiratory syncytial virus (RSV) and methods of use
US9493578B2 (en)	2009-09-02	2016-11-15	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781519A1 (en)	2009-09-16	2011-03-24	Genentech, Inc.	Coiled coil and/or tether containing protein complexes and uses thereof
WO2011035205A2 (en)	2009-09-18	2011-03-24	Calmune Corporation	Antibodies against candida, collections thereof and methods of use
US20120316071A1 (en)	2009-11-04	2012-12-13	Vaughn Smider	Methods for affinity maturation-based antibody optimization
TW201120210A (en)	2009-11-05	2011-06-16	Hoffmann La Roche	Glycosylated repeat-motif-molecule conjugates
TWI600760B (zh) *	2009-11-05	2017-10-01	建南德克公司	分泌異源多肽之方法及組合物
RS66008B1 (sr)	2010-03-10	2024-10-31	Genmab As	Monoklonska antitela protiv c-met
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
MX2012012992A (es) *	2010-05-14	2012-12-17	Genentech Inc	Metodos de tratamiento.
CA3051311A1 (en)	2010-05-27	2011-12-01	Genmab A/S	Monoclonal antibodies against her2
EP2575880B1 (en)	2010-05-27	2019-01-16	Genmab A/S	Monoclonal antibodies against her2 epitope
CA3062786C (en)	2010-07-09	2022-04-19	Janssen Vaccines & Prevention B.V.	Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
CA2806252C (en)	2010-07-29	2019-05-14	Xencor, Inc.	Antibodies with modified isoelectric points
CA2807278A1 (en)	2010-08-24	2012-03-01	F. Hoffmann - La Roche Ag	Bispecific antibodies comprising a disulfide stabilized - fv fragment
EP3264089A1 (en)	2010-08-31	2018-01-03	Genentech, Inc.	Biomarkers and methods of treatment
RU2604490C2 (ru)	2010-11-05	2016-12-10	Займворкс Инк.	ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
WO2012075340A2 (en)	2010-12-01	2012-06-07	Alderbio Holdings Llc	Anti-ngf compositions and use thereof
WO2012085111A1 (en)	2010-12-23	2012-06-28	F. Hoffmann-La Roche Ag	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JP6161540B2 (ja)	2011-02-04	2017-07-12	ジェネンテック，インコーポレイテッド	Ｆｃ変異体及びそれらの生産方法
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
JP5764677B2 (ja) *	2011-02-28	2015-08-19	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	抗原結合タンパク質
CN103403025B (zh) *	2011-02-28	2016-10-12	弗·哈夫曼-拉罗切有限公司	单价抗原结合蛋白
KR20160044598A (ko)	2011-03-29	2016-04-25	로슈 글리카트 아게	항체 Fc 변이체
AU2012275233A1 (en)	2011-06-30	2013-11-28	Genentech, Inc.	Anti-c-met antibody formulations
WO2013033008A2 (en)	2011-08-26	2013-03-07	Merrimack Pharmaceuticals, Inc.	Tandem fc bispecific antibodies
KR20140064971A (ko)	2011-09-19	2014-05-28	제넨테크, 인크.	c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
US9201074B2 (en)	2011-09-20	2015-12-01	Eli Lilly And Company	Anti-c-Met antibodies
US12466897B2 (en)	2011-10-10	2025-11-11	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EA030440B1 (ru)	2011-10-24	2018-08-31	Галозим, Инк.	Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения
KR102052774B1 (ko)	2011-11-04	2019-12-04	자임워크스 인코포레이티드	Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
AU2012340826A1 (en) *	2011-11-21	2014-05-29	Genentech, Inc.	Purification of anti-c-met antibodies
WO2013119966A2 (en)	2012-02-10	2013-08-15	Genentech, Inc.	Single-chain antibodies and other heteromultimers
JP6849868B2 (ja) *	2012-05-10	2021-03-31	ザイムワークス，インコーポレイテッド	シングルアーム一価抗体構築物およびその用途
US9499634B2 (en)	2012-06-25	2016-11-22	Zymeworks Inc.	Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
KR20150030744A (ko)	2012-06-27	2015-03-20	에프. 호프만-라 로슈 아게	표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru)	2012-06-27	2017-12-20	Ф. Хоффманн-Ля Рош Аг	Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
SG11201408538PA (en)	2012-07-13	2015-02-27	Roche Glycart Ag	Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
JP6273205B2 (ja)	2012-10-05	2018-01-31	協和発酵キリン株式会社	ヘテロダイマータンパク質組成物
WO2014062856A1 (en)	2012-10-16	2014-04-24	Halozyme, Inc.	Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2914629A1 (en)	2012-11-05	2015-09-09	MAB Discovery GmbH	Method for the production of multispecific antibodies
EP2727941A1 (en)	2012-11-05	2014-05-07	MAB Discovery GmbH	Method for the production of multispecific antibodies
US9914785B2 (en)	2012-11-28	2018-03-13	Zymeworks Inc.	Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9856319B2 (en)	2012-12-28	2018-01-02	Abbvie Inc.	Monovalent binding proteins
ITTO20130012A1 (it)	2013-01-09	2014-07-10	Metheresis Translational Res S A	Nuovi frammenti anticorpali, relative composizioni ed usi
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
HRP20191865T1 (hr)	2013-01-14	2020-01-10	Xencor, Inc.	Novi heterodimerni proteini
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
WO2014113510A1 (en)	2013-01-15	2014-07-24	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
MX2015011712A (es)	2013-03-06	2016-04-04	Merrimack Pharmaceuticals Inc	Anticerpos biespecificos fc en fila anti-c-met.
US9168300B2 (en)	2013-03-14	2015-10-27	Oncomed Pharmaceuticals, Inc.	MET-binding agents and uses thereof
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
CA3093606A1 (en)	2013-03-15	2014-09-18	Xencor, Inc.	Heterodimeric proteins for induction of t cells
US20160114057A1 (en) *	2013-05-24	2016-04-28	Zyeworks Inc.	Modular protein drug conjugate therapeutic
CA2913370C (en)	2013-05-31	2022-12-13	Zymeworks Inc.	Heteromultimers with reduced or silenced effector function
RU2016115866A (ru)	2013-10-11	2017-11-16	Ф. Хоффманн-Ля Рош Аг	Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
WO2015139046A1 (en)	2014-03-14	2015-09-17	Genentech, Inc.	Methods and compositions for secretion of heterologous polypeptides
EP3122900A1 (en)	2014-03-24	2017-02-01	F. Hoffmann-La Roche AG	Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP3954713A3 (en)	2014-03-28	2022-03-30	Xencor, Inc.	Bispecific antibodies that bind to cd38 and cd3
EP3207130B1 (en)	2014-10-14	2019-08-07	Halozyme, Inc.	Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CN116333153A (zh)	2014-11-26	2023-06-27	森科股份有限公司	结合cd3和肿瘤抗原的异二聚体抗体
EP3223907A2 (en)	2014-11-26	2017-10-04	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
PL3227332T3 (pl)	2014-12-03	2020-06-15	F. Hoffmann-La Roche Ag	Wielospecyficzne przeciwciała
EP3233916A4 (en)	2014-12-19	2018-06-06	Alder Biopharmaceuticals, Inc.	Humanized anti-acth antibodies and use thereof
WO2016105450A2 (en)	2014-12-22	2016-06-30	Xencor, Inc.	Trispecific antibodies
SG11201706014PA (en)	2015-02-05	2017-08-30	Chugai Pharmaceutical Co Ltd	Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
ES2761726T3 (es)	2015-03-06	2020-05-20	Hoffmann La Roche	DsbA y DsbC ultrapurificadas y procedimientos de preparación y uso de las mismas
EP3302552A1 (en)	2015-06-02	2018-04-11	H. Hoffnabb-La Roche Ag	Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
AR105634A1 (es)	2015-09-18	2017-10-25	Chugai Pharmaceutical Co Ltd	Anticuerpos que se unen a il 8 y sus usos
WO2017053469A2 (en)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Cd3 binding polypeptides
BR112018010360A2 (en)	2015-11-24	2018-12-04	Annexon, Inc.	anti-c1q complement factor fab fragments and uses thereof
KR20180085800A (ko)	2015-12-07	2018-07-27	젠코어 인코포레이티드	Cd3 및 psma에 결합하는 이종이합체성 항체
KR102824067B1 (ko)	2016-04-15	2025-06-23	알파인 이뮨 사이언시즈, 인코포레이티드	Icos 리간드 변이체 면역조절 단백질 및 그의 용도
EP3443000B1 (en)	2016-04-15	2025-11-12	Alpine Immune Sciences, Inc.	Cd80 variant immunomodulatory proteins and uses thereof
CA3024465A1 (en)	2016-05-17	2017-11-23	Genentech, Inc.	Stromal gene signatures for diagnosis and use in immunotherapy
IL263542B2 (en)	2016-06-14	2024-10-01	Xencor Inc	Bispecific antibodies inhibit immunological checkpoint
EP3472177B1 (en)	2016-06-17	2024-08-14	F. Hoffmann-La Roche AG	Purification of multispecific antibodies
KR20190020341A (ko)	2016-06-28	2019-02-28	젠코어 인코포레이티드	소마토스타틴 수용체 2에 결합하는 이종이량체 항체
US11471488B2 (en)	2016-07-28	2022-10-18	Alpine Immune Sciences, Inc.	CD155 variant immunomodulatory proteins and uses thereof
CN110088127A (zh)	2016-07-28	2019-08-02	高山免疫科学股份有限公司	Cd155变体免疫调节蛋白及其用途
US11834490B2 (en)	2016-07-28	2023-12-05	Alpine Immune Sciences, Inc.	CD112 variant immunomodulatory proteins and uses thereof
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN110214148A (zh)	2016-10-14	2019-09-06	Xencor股份有限公司	含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
WO2018089829A1 (en)	2016-11-10	2018-05-17	Fortis Therapeutics, Inc.	Cd46-specific effector cells and uses thereof
TWI782930B (zh)	2016-11-16	2022-11-11	美商再生元醫藥公司	抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN110494565A (zh)	2016-12-02	2019-11-22	朱诺治疗学股份有限公司	工程化b细胞及相关组合物和方法
TW201825515A (zh)	2017-01-04	2018-07-16	美商伊繆諾金公司	Ｍｅｔ抗體以及其免疫結合物及用途
CA3054068A1 (en)	2017-03-16	2018-09-20	Alpine Immune Sciences, Inc.	Cd80 variant immunomodulatory proteins and uses thereof
CN110809581A (zh)	2017-03-16	2020-02-18	高山免疫科学股份有限公司	Pd-l2变体免疫调节蛋白及其用途
LT3596116T (lt)	2017-03-16	2023-11-10	Alpine Immune Sciences, Inc.	Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
MY200973A (en)	2017-04-11	2024-01-26	Inhibrx Inc	Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
US10781435B2 (en)	2017-06-22	2020-09-22	Catalyst Biosciences, Inc.	Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
AU2018291497A1 (en)	2017-06-30	2020-01-16	Xencor, Inc.	Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
CA3070297A1 (en)	2017-08-11	2019-02-14	Genentech, Inc.	Anti-cd8 antibodies and uses thereof
KR102813968B1 (ko)	2017-10-10	2025-05-29	알파인 이뮨 사이언시즈, 인코포레이티드	Ctla-4 변이체 면역조절 단백질 및 이의 용도
MX2020004540A (es)	2017-10-18	2020-08-03	Alpine Immune Sciences Inc	Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en)	2017-11-08	2020-05-28	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-PD-1 sequences
MX2020006322A (es)	2017-12-19	2020-09-18	Xencor Inc	Proteinas de fusion il-2 fc modificadas.
EP3735417A1 (en)	2018-01-03	2020-11-11	Alpine Immune Sciences, Inc.	Multi-domain immunomodulatory proteins and methods of use thereof
CN112469477A (zh)	2018-04-04	2021-03-09	Xencor股份有限公司	与成纤维细胞活化蛋白结合的异源二聚体抗体
IL323061A (en)	2018-04-11	2025-10-01	Inhibrx Biosciences Inc	Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
AU2019256539A1 (en)	2018-04-18	2020-11-26	Xencor, Inc.	PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
EP3781598A1 (en)	2018-04-18	2021-02-24	Xencor, Inc.	Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
WO2019241758A1 (en)	2018-06-15	2019-12-19	Alpine Immune Sciences, Inc.	Pd-1 variant immunomodulatory proteins and uses thereof
WO2020014306A1 (en)	2018-07-10	2020-01-16	Immunogen, Inc.	Met antibodies and immunoconjugates and uses thereof
CN112789294A (zh)	2018-07-24	2021-05-11	印希比股份有限公司	含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
TW202021618A (zh)	2018-08-17	2020-06-16	美商２３與我有限公司	抗ｉｌ１ｒａｐ抗體及其使用方法
CN113544144A (zh)	2018-09-19	2021-10-22	高山免疫科学股份有限公司	变体cd80融合蛋白和相关构建体的方法和用途
US20210371519A1 (en) *	2018-09-21	2021-12-02	University Of Cincinnati	Suppressing IgE-Mediated Allergy by Desensitization with Monovalent Anti-FCeR1a Monoclonal Antibody
SG11202103192RA (en)	2018-10-03	2021-04-29	Xencor Inc	Il-12 heterodimeric fc-fusion proteins
IT201800009282A1 (it) *	2018-10-09	2020-04-09	Metis Prec Medicine Sb Srl	Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
WO2020076970A1 (en)	2018-10-11	2020-04-16	Inhibrx, Inc.	B7h3 single domain antibodies and therapeutic compositions thereof
US11208485B2 (en)	2018-10-11	2021-12-28	Inhibrx, Inc.	PD-1 single domain antibodies and therapeutic compositions thereof
CA3115089A1 (en)	2018-10-11	2020-04-16	Inhibrx, Inc.	Dll3 single domain antibodies and therapeutic compositions thereof
TW202506736A (zh)	2018-10-11	2025-02-16	美商因荷布瑞克斯生物科學公司	5t4單域抗體及其治療性組合物
CN113727998A (zh)	2018-11-30	2021-11-30	高山免疫科学股份有限公司	Cd86变体免疫调节蛋白及其用途
AR117327A1 (es)	2018-12-20	2021-07-28	23Andme Inc	Anticuerpos anti-cd96 y métodos de uso de estos
BR112021010374A2 (pt)	2018-12-21	2021-08-24	23Andme, Inc.	Anticorpos anti-il-36 e métodos de uso dos mesmos
PE20211664A1 (es)	2018-12-28	2021-08-26	Catalyst Biosciences Inc	Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso
US11613744B2 (en)	2018-12-28	2023-03-28	Vertex Pharmaceuticals Incorporated	Modified urokinase-type plasminogen activator polypeptides and methods of use
AU2020232605A1 (en)	2019-03-01	2021-10-21	Xencor, Inc.	Heterodimeric antibodies that bind ENPP3 and CD3
AU2020257238A1 (en)	2019-04-17	2021-12-02	Alpine Immune Sciences, Inc.	Methods and uses of variant ICOS Ligand (ICOSL) fusion proteins
CN110174456B (zh) *	2019-06-11	2021-09-21	华润双鹤药业股份有限公司	一种测定肺表面活性物质蛋白的方法及其应用
KR20220063185A (ko)	2019-09-16	2022-05-17	리제너론 파마슈티칼스 인코포레이티드	면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
CN115380047A (zh)	2020-01-29	2022-11-22	印希比股份有限公司	Cd28单结构域抗体及其多价和多特异性构建体
CN115812077A (zh)	2020-05-08	2023-03-17	高山免疫科学股份有限公司	April和baff抑制性免疫调节蛋白及其使用方法
WO2021231976A1 (en)	2020-05-14	2021-11-18	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
KR20230029671A (ko)	2020-05-27	2023-03-03	아리아리스 테라퓨틱스, 인크.	항-인간 nr1 항체 유도체
BR112022024339A2 (pt)	2020-05-29	2022-12-27	23Andme Inc	Anticorpos anti cd200r1 e métodos de uso dos mesmos
CN116234824A (zh)	2020-06-22	2023-06-06	阿尔米雷尔有限公司	抗il-36抗体及其使用方法
KR20230066149A (ko)	2020-08-07	2023-05-12	포티스 테라퓨틱스, 인크.	Cd46을 표적화하는 면역접합체 및 이의 사용 방법
KR102607909B1 (ko)	2020-08-19	2023-12-01	젠코어 인코포레이티드	항-cd28 조성물
JP2023541627A (ja)	2020-09-14	2023-10-03	イシュノスサイエンシズソシエテアノニム	Ｉｌ１ｒａｐに結合する抗体及びその使用
JP2024511319A (ja)	2021-03-09	2024-03-13	ゼンコアインコーポレイテッド	Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja)	2021-03-10	2024-02-29	ゼンコアインコーポレイテッド	Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
WO2022236335A1 (en)	2021-05-07	2022-11-10	Alpine Immune Sciences, Inc.	Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
US12486322B2 (en)	2021-12-13	2025-12-02	Annexon, Inc.	Anti-complement factor C1q antibodies with single binding arms and uses thereof
WO2023168426A1 (en)	2022-03-03	2023-09-07	Enosi Therapeutics Corporation	Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2023172883A1 (en)	2022-03-07	2023-09-14	Alpine Immune Sciences, Inc.	Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
IL316249A (en) *	2022-05-02	2024-12-01	Novo Nordisk As	Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
EP4598557A2 (en)	2022-10-04	2025-08-13	Alpine Immune Sciences, Inc.	Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
WO2024102948A1 (en)	2022-11-11	2024-05-16	Celgene Corporation	Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
WO2024186690A2 (en)	2023-03-03	2024-09-12	Enosi Therapeutics Corporation	Oligo-trap fusion proteins (ofps) and uses thereof
TW202448953A (zh)	2023-06-01	2024-12-16	法商皮爾法伯製藥公司	用於腫瘤及轉移之治療的基於沉默抗體的抗met建構物
WO2025038668A1 (en)	2023-08-14	2025-02-20	Voro Therapeutics, Inc.	Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025104604A1 (en)	2023-11-14	2025-05-22	Janssen Pharmaceuticals, Inc.	Anti-respiratory syncytial virus antibodies and uses thereof
WO2025144958A1 (en) *	2023-12-29	2025-07-03	AffyImmune Therapeutics Inc.	Novel c-met binding agents and methods of treatment
WO2025240670A2 (en)	2024-05-15	2025-11-20	Abalytics Oncology, Inc.	Anti-pd-1 antibodies and related binding molecules and methods and uses thereof

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US526365A (en) *		1894-09-18		Jacquard mechanism for looms
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3896111A (en)	1973-02-20	1975-07-22	Research Corp	Ansa macrolides
US4151042A (en)	1977-03-31	1979-04-24	Takeda Chemical Industries, Ltd.	Method for producing maytansinol and its derivatives
US4137230A (en)	1977-11-14	1979-01-30	Takeda Chemical Industries, Ltd.	Method for the production of maytansinoids
USRE30985E (en)	1978-01-01	1982-06-29		Serum-free cell culture media
US4265814A (en)	1978-03-24	1981-05-05	Takeda Chemical Industries	Matansinol 3-n-hexadecanoate
US4307016A (en)	1978-03-24	1981-12-22	Takeda Chemical Industries, Ltd.	Demethyl maytansinoids
JPS5562090A (en)	1978-10-27	1980-05-10	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS5566585A (en)	1978-11-14	1980-05-20	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55164687A (en)	1979-06-11	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
US4256746A (en)	1978-11-14	1981-03-17	Takeda Chemical Industries	Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en)	1979-01-31	1980-08-05	Takeda Chem Ind Ltd	20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en)	1979-06-05	1980-12-18	Takeda Chem Ind Ltd	Antibiotic c-15003pnd and its preparation
JPS55164685A (en)	1979-06-08	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
JPS55164686A (en)	1979-06-11	1980-12-22	Takeda Chem Ind Ltd	Novel maytansinoid compound and its preparation
US4309428A (en)	1979-07-30	1982-01-05	Takeda Chemical Industries, Ltd.	Maytansinoids
JPS5645483A (en)	1979-09-19	1981-04-25	Takeda Chem Ind Ltd	C-15003phm and its preparation
JPS5645485A (en)	1979-09-21	1981-04-25	Takeda Chem Ind Ltd	Production of c-15003pnd
EP0028683A1 (en)	1979-09-21	1981-05-20	Takeda Chemical Industries, Ltd.	Antibiotic C-15003 PHO and production thereof
US4342566A (en) *	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
WO1982001188A1 (en)	1980-10-08	1982-04-15	Takeda Chemical Industries Ltd	4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en)	1980-11-03	1984-05-22	Standard Oil Company	Impact improvement of high nitrile resins
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4313946A (en)	1981-01-27	1982-02-02	The United States Of America As Represented By The Secretary Of Agriculture	Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en)	1981-01-27	1982-02-16	The United States Of America As Represented By The Secretary Of Agriculture	Method of controlling the European corn borer with trewiasine
JPS57192389A (en)	1981-05-20	1982-11-26	Takeda Chem Ind Ltd	Novel maytansinoid
US4601978A (en)	1982-11-24	1986-07-22	The Regents Of The University Of California	Mammalian metallothionein promoter system
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8318575D0 (en)	1983-07-08	1983-08-10	Cobbold S P	Antibody preparations
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4965199A (en)	1984-04-20	1990-10-23	Genentech, Inc.	Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970198A (en)	1985-10-17	1990-11-13	American Cyanamid Company	Antitumor antibiotics (LL-E33288 complex)
US5169939A (en)	1985-05-21	1992-12-08	Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College	Chimeric antibodies
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
IL85035A0 (en) *	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5079233A (en)	1987-01-30	1992-01-07	American Cyanamid Company	N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
AU600575B2 (en) *	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
US4975278A (en)	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5053394A (en)	1988-09-21	1991-10-01	American Cyanamid Company	Targeted forms of methyltrithio antitumor agents
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en)	1987-10-30	1998-06-23	American Cyanamid Company	Process for preparing targeted forms of methyltrithio antitumor agents
EP0435911B1 (en)	1988-09-23	1996-03-13	Cetus Oncology Corporation	Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5362716A (en) *	1989-12-27	1994-11-08	The United States Of America As Represented By The Department Of Health And Human Services	Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US5871959A (en) *	1989-12-27	1999-02-16	The United States Of America As Represented By The Department Of Health And Human Services	Method of producing hepatocycte growth factor/scatter factor and related cell lines
GB9009106D0 (en) *	1990-04-23	1990-06-20	3I Res Expl Ltd	Processes and intermediates for synthetic antibody derivatives
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5968509A (en) *	1990-10-05	1999-10-19	Btp International Limited	Antibodies with binding affinity for the CD3 antigen
US5264365A (en)	1990-11-09	1993-11-23	Board Of Regents, The University Of Texas System	Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) *	1990-11-09	1996-04-16	Board Of Regents, The University Of Texas System	Bacterial host strains for producing proteolytically sensitive polypeptides
US5227158A (en) *	1991-06-10	1993-07-13	Genentech, Inc.	Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
WO1993006217A1 (en) *	1991-09-19	1993-04-01	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5362852A (en)	1991-09-27	1994-11-08	Pfizer Inc.	Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5207152A (en) *	1991-10-28	1993-05-04	Wettlaufer Dale E	Compact juice machine
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2118508A1 (en) *	1992-04-24	1993-11-11	Elizabeth S. Ward	Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5328837A (en) *	1992-05-18	1994-07-12	Genentech, Inc.	Hepatocyte growth factor protease domain variants
US5316921A (en) *	1992-05-18	1994-05-31	Genentech, Inc.	Single-chain hepatocyte growth factor variants
PT642580E (pt) *	1992-05-18	2003-01-31	Genentech Inc	Variantes de factor de crescimento dos hepatocitos
ES2091684T3 (es)	1992-11-13	1996-11-01	Idec Pharma Corp	Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
WO1994029351A2 (en)	1993-06-16	1994-12-22	Celltech Limited	Antibodies
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5639635A (en)	1994-11-03	1997-06-17	Genentech, Inc.	Process for bacterial production of polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5840523A (en) *	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
DE19512484A1 (de)	1995-04-04	1996-10-17	Bayer Ag	Kohlenhydratmodifizierte Cytostatika
US6121022A (en) *	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
US6214344B1 (en) *	1995-06-02	2001-04-10	Genetech, Inc.	Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) *	1995-06-02	1997-07-08	Genentech, Inc.	Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en)	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
AU2660397A (en) *	1996-04-05	1997-10-29	Board Of Regents, The University Of Texas System	Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en)	1997-06-09	2000-07-04	Board Of Regents, The University Of Texas System	Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
DE69937291T2 (de)	1998-04-02	2008-07-10	Genentech, Inc., South San Francisco	Antikörpervarianten und fragmente davon
DE19858253A1 (de) *	1998-12-17	2000-06-21	Aventis Pharma Gmbh	Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden
WO2001045746A2 (en)	1999-12-24	2001-06-28	Genentech, Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
US6548237B2 (en) *	2000-07-04	2003-04-15	Fuji Photo Film Co., Ltd.	Silver halide color photographic lightsensitive material and method of forming color image using the same
US6979556B2 (en) *	2000-12-14	2005-12-27	Genentech, Inc.	Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US20040002587A1 (en) *	2002-02-20	2004-01-01	Watkins Jeffry D.	Fc region variants
EP1391213A1 (en)	2002-08-21	2004-02-25	Boehringer Ingelheim International GmbH	Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
GB0230203D0 (en) *	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
WO2005063816A2 (en) *	2003-12-19	2005-07-14	Genentech, Inc.	Monovalent antibody fragments useful as therapeutics

2004
- 2004-12-17 WO PCT/US2004/042619 patent/WO2005063816A2/en not_active Ceased
- 2004-12-17 RU RU2006126097/13A patent/RU2006126097A/ru not_active Application Discontinuation
- 2004-12-17 JP JP2006545515A patent/JP2008504007A/ja active Pending
- 2004-12-17 BR BRPI0417107-1A patent/BRPI0417107A/pt not_active IP Right Cessation
- 2004-12-17 CA CA002548757A patent/CA2548757A1/en not_active Abandoned
- 2004-12-17 EP EP04814762A patent/EP1718677B1/en not_active Expired - Lifetime
- 2004-12-17 DK DK04814762.3T patent/DK1718677T3/da active
- 2004-12-17 ZA ZA200604864A patent/ZA200604864B/en unknown
- 2004-12-17 AT AT04814762T patent/ATE554107T1/de active
- 2004-12-17 PT PT04814762T patent/PT1718677E/pt unknown
- 2004-12-17 MX MXPA06006985A patent/MXPA06006985A/es active IP Right Grant
- 2004-12-17 PL PL04814762T patent/PL1718677T3/pl unknown
- 2004-12-17 CN CNA2004800419058A patent/CN1922210A/zh active Pending
- 2004-12-17 US US11/015,558 patent/US20050227324A1/en not_active Abandoned
- 2004-12-17 ES ES04814762T patent/ES2384569T3/es not_active Expired - Lifetime
- 2004-12-17 AU AU2004309347A patent/AU2004309347B2/en not_active Ceased
- 2004-12-17 KR KR1020067014346A patent/KR100956913B1/ko not_active Expired - Fee Related
- 2004-12-17 NZ NZ547438A patent/NZ547438A/en not_active IP Right Cessation
- 2004-12-17 EP EP10182225A patent/EP2275448A3/en not_active Withdrawn
- 2004-12-17 SI SI200431892T patent/SI1718677T1/sl unknown
2006
- 2006-05-24 IL IL175885A patent/IL175885A/en not_active IP Right Cessation
- 2006-10-03 US US11/538,375 patent/US20080063641A1/en not_active Abandoned
2011
- 2011-02-23 IL IL211367A patent/IL211367A/en not_active IP Right Cessation
- 2011-03-10 US US13/045,316 patent/US20110200596A1/en not_active Abandoned
- 2011-04-19 JP JP2011093365A patent/JP2011172585A/ja not_active Withdrawn
2012
- 2012-06-12 CY CY20121100532T patent/CY1112862T1/el unknown
2013
- 2013-04-15 US US13/863,312 patent/US20140205593A1/en not_active Abandoned
2016
- 2016-04-15 US US15/130,047 patent/US20160222115A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE554107T1 (de)	2012-05-15
EP2275448A2 (en)	2011-01-19
BRPI0417107A (pt)	2007-02-06
AU2004309347B2 (en)	2010-03-04
MXPA06006985A (es)	2006-08-31
PL1718677T3 (pl)	2012-09-28
ES2384569T3 (es)	2012-07-09
ZA200604864B (en)	2007-10-31
KR20060130610A (ko)	2006-12-19
IL211367A0 (en)	2011-04-28
IL175885A (en)	2011-02-28
WO2005063816A3 (en)	2005-08-25
EP2275448A3 (en)	2013-02-06
US20080063641A1 (en)	2008-03-13
PT1718677E (pt)	2012-07-18
IL211367A (en)	2014-06-30
CN1922210A (zh)	2007-02-28
EP1718677A2 (en)	2006-11-08
SI1718677T1 (sl)	2012-08-31
NZ547438A (en)	2010-01-29
AU2004309347A1 (en)	2005-07-14
US20110200596A1 (en)	2011-08-18
HK1099027A1 (en)	2007-08-03
US20160222115A1 (en)	2016-08-04
US20140205593A1 (en)	2014-07-24
RU2006126097A (ru)	2008-02-20
EP1718677B1 (en)	2012-04-18
JP2011172585A (ja)	2011-09-08
CA2548757A1 (en)	2005-07-14
IL175885A0 (en)	2006-10-05
US20050227324A1 (en)	2005-10-13
WO2005063816A2 (en)	2005-07-14
KR100956913B1 (ko)	2010-05-11
CY1112862T1 (el)	2016-04-13
JP2008504007A (ja)	2008-02-14

Publication	Publication Date	Title
DK1718677T3 (da)	2012-07-09	Monovalente antistoffragmenter egnede som terapeutiske midler
CY1112277T1 (el)	2015-12-09	ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
NO20041917D0 (no)	2004-05-10	Spesifikke midler som binder humant angiopoietin-2
NO20063624L (no)	2006-10-03	FC region varianter
ATE553775T1 (de)	2012-05-15	Impstoffzusammesetzung
DE60200746D1 (de)	2004-08-19	Kautschukzusammensetzung
NO20050132D0 (no)	2005-01-11	Vaksinesammensetning
ATE289640T1 (de)	2005-03-15	Amidofunktionelle aminopolydiorganosiloxane
DK1847611T3 (da)	2010-01-04	Rhamnose-inducerbart ekspressionssystem
DE60335716D1 (de)	2011-02-24	Beschleuniger-zusammensetzung
DE60212442D1 (de)	2006-07-27	Kautschukzusammensetzung
BRPI0417992B8 (pt)	2021-05-25	métodos para purificar fsh humano recombinante ou uma variante de fsh
NO20052149D0 (no)	2005-05-02	Vaksine.
ATE461219T1 (de)	2010-04-15	Therapeutische humanisierte antikörper gegen cd45-isoformen
DE60237109D1 (de)	2010-09-02	Rbesserte transistoreigenschaften
DE60129749D1 (de)	2007-09-13	Kautschukzusammensetzung
UY28344A1 (es)	2005-01-31	Nuevos compuestos
ATE513564T1 (de)	2011-07-15	Immunogener rekombinanter antikörper
EP1420818A4 (en)	2008-07-02	ANTIGENIC COMPOSITIONS
BRPI0417205A (pt)	2007-02-06	composições farmacêuticas
DE50205836D1 (de)	2006-04-20	Emulgator-gemisch
NO20053363D0 (no)	2005-07-11	Malrettede enkle epitoper.
DE50203703D1 (de)	2005-08-25	Emulgator-gemisch
DE60236587D1 (de)	2010-07-15	Latexzusammensetzung
ITTO20020744A1 (it)	2003-02-25	Composizione.